<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v =2.1 7.9.post6+86293ac&amp;ff=20230720142913&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;ff=20230720142913&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 7 月 20 日星期四 18:29:14 +0000</lastbuilddate><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>球囊肺血管成形术治疗慢性血栓栓塞性肺动脉高压：ESC工作组关于肺循环和右心室功能的临床共识声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37470202/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description> 2022 年欧洲心脏病学会 (ESC)/欧洲呼吸学会 (ERS) 肺动脉高压 (PH) 诊断和治疗指南中描述的慢性血栓栓塞性肺动脉高压 (CTEPH) 目前的治疗方案包括肺动脉内膜切除术 (PEA)、球囊肺血管成形术 (BPA) 和医学科学相结合的多模式方法，以针对主要血管肺血管病变和微血管病变。如今，BPA >;1700... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 20:ehad413.doi: 10.1093/eurheartj/ehad413. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> 2022 年欧洲心脏病学会 (ESC)/欧洲呼吸学会 (ERS) 肺动脉高压 (PH) 诊断和治疗指南中描述的慢性血栓栓塞性肺动脉高压 (CTEPH) 目前的治疗方案包括肺动脉内膜切除术 (PEA)、球囊肺血管成形术 (BPA) 和医学科学相结合的多模式方法，以针对主要血管肺血管病变。如今，来自美国亚洲中心的文献报道了超过 1700 名患者的 BPA以及欧洲；更多的患者在文献报道之外接受治疗。随着 BPA 成为 CTEPH 患者常规护理的一部分，安全有效的护理提供基准变得越来越重要。德尔菲法用于非证据基础的陈述。首先，提供了解剖学命名法和血管病变的描述。其次，概述了完全 BPA 的治疗目标和定义。第三，提出了并发症的定义，这可能是涉及 BPA 的研究标准化报告的基础。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37470202/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37470202</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad413>10.1093/eurheartj/ehad413</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37470202</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:creator>艾琳·M·朗</dc:creator><dc:creator>阿恩·K·安德烈森</dc:creator><dc:creator>阿斯格·安徒生</dc:creator><dc:creator>海伦·布瓦伊斯特</dc:creator><dc:creator>格里·科格兰</dc:creator><dc:creator>皮拉尔·埃斯克里巴诺-苏比亚斯</dc:creator><dc:creator>Pavel Jansa更多</dc:creator><dc:creator>格热戈日·科佩克</dc:creator><dc:creator>马尔钦·库尔兹纳</dc:creator><dc:creator>松原博美</dc:creator><dc:creator>伯恩哈德·克里斯蒂安·迈耶</dc:creator><dc:creator>马西米利亚诺·帕拉齐尼</dc:creator><dc:creator>马可·C·波斯特</dc:creator><dc:creator>皮奥特·普鲁什奇克</dc:creator><dc:creator>洛伦兹·拉贝尔</dc:creator><dc:creator>马雷克·罗伊克</dc:creator><dc:creator>斯蒂芬·罗森克兰兹</dc:creator><dc:creator>克里斯托夫·维登罗斯</dc:creator><dc:creator>卡罗·雷德林·韦尔勒</dc:creator><dc:creator>菲利普·布雷诺</dc:creator><dc:date>2023-07-20</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>球囊肺血管成形术治疗慢性血栓栓塞性肺动脉高压：ESC工作组关于肺循环和右心室功能的临床共识声明</dc:title><dc:identifier>下午：37470202</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad413</dc:identifier></item><item><title> Danicamtiv 增加肌球蛋白募集并改变心肌的跨桥循环</title><link/>https://pubmed.ncbi.nlm.nih.gov/37470183/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description>结论：正如 Danicamtiv 的详细研究所证明的那样，增加肌球蛋白募集和改变跨桥循环是增加心肌力和钙敏感性的两种机制。肌球蛋白激活剂如 Danicamtiv 可以治疗遗传性扩张型心肌病的致病性低收缩表型。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 7 月 20 日。doi：10.1161/CIRCRESAHA.123.322629。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：调节肌球蛋白功能是心肌病患者的一种新型治疗方法。Danicamtiv 是一种新型肌球蛋白激活剂，具有良好的临床前数据，目前正在进行临床试验。虽然已知 danicamtiv 可以增加力量和心肌细胞收缩力而不影响钙水平，但缺乏关于其作用方式的详细机制研究。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用透化的猪心脏组织和肌原纤维进行X射线衍射和力学测量，并使用遗传性扩张型心肌病小鼠模型来评估danicamtiv纠正收缩缺陷的能力。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：Danicamtiv 通过增加处于开启状态的肌球蛋白数量和减慢跨桥周转来增加力和钙敏感性。我们的详细分析表明，抑制 ADP 释放会导致跨桥周转减少，横桥保持更长的附着时间并延长肌原纤维松弛。Danicamtiv 纠正了脱膜组织中钙敏感性的降低、完整心脏组织中的异常抽搐和幅度动力学以及整个器官中射血分数的降低。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：正如 Danicamtiv 的详细研究所证明的那样，增加肌球蛋白募集和改变跨桥循环是增加心肌力和钙敏感性的两种机制。肌球蛋白激活剂如 Danicamtiv 可以治疗遗传性扩张型心肌病的致病性低收缩表型。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37470183/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37470183</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322629>10.1161/CIRCRESAHA.123.322629</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37470183</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:creator>克里斯蒂娜·B·库克</dc:creator><dc:creator>萨菲·莫兰</dc:creator><dc:creator>——凯拉·L·特纳</dc:creator><dc:creator>马伟康</dc:creator><dc:creator>艾米·马丁森</dc:creator><dc:creator>加林娜·弗林特</dc:creator><dc:creator>林琪</dc:creator><dc:creator>高承前</dc:creator><dc:creator>郑雅涵</dc:creator><dc:creator>蒂莫西·麦克米伦</dc:creator><dc:creator>克里斯蒂安·曼德里基</dc:creator><dc:creator>马克斯·马奥尼-谢弗</dc:creator><dc:creator>——杰里米·C·弗里曼</dc:creator><dc:creator>伊利亚·加布里埃拉·科斯塔莱斯·阿里纳斯</dc:creator><dc:creator>涂安宇</dc:creator><dc:creator>托马斯·C·欧文</dc:creator><dc:creator>迈克尔·吉夫斯</dc:creator><dc:creator>——伯特兰·C·W·坦纳</dc:creator><dc:creator>——迈克尔·雷尼尔</dc:creator><dc:creator>詹妮弗·戴维斯</dc:creator><dc:creator>法里德·穆萨维·哈拉米</dc:creator><dc:date>2023-07-20</dc:date><dc:source>流通研究</dc:source><dc:title>Danicamtiv 增加肌球蛋白募集并改变心肌的跨桥循环</dc:title><dc:identifier>下午：37470183</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322629</dc:identifier></item><item><title>仪器变量、计算机试验模拟和心脏病学前沿分析：能力越大，责任越大</title><link/>https://pubmed.ncbi.nlm.nih.gov/37470166/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 20:ehad248.doi: 10.1093/eurheartj/ehad248. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37470166/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37470166</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad248>10.1093/eurheartj/ehad248</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37470166</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:creator>布里多格·尼克·奥达·布伊</dc:creator><dc:creator>约翰·威廉·麦克沃伊</dc:creator><dc:date>2023-07-20</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>仪器变量、计算机试验模拟和心脏病学前沿分析：能力越大，责任越大</dc:title><dc:identifier>下午：37470166</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad248</dc:identifier></item><item><title>回复：在没有真正的超声心动图评估的情况下诊断假体与患者不匹配：我们的研究是否正确？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37468194/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):e29.doi: 10.1016/j.jacc.2023.05.029。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468194/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37468194</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.029>10.1016/j.jacc.2023.05.029</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468194</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>迈克尔·迪斯莫尔</dc:creator><dc:creator>娜塔莉·格拉泽</dc:creator><dc:creator>安德斯·佛朗哥-塞雷塞达</dc:creator><dc:creator>乌尔里克·萨蒂皮</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>回复：在没有真正的超声心动图评估的情况下诊断假体与患者不匹配：我们的研究是否正确？</dc:title><dc:identifier>下午：37468194</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.029</dc:identifier></item><item><title>在没有真正的超声心动图评估的情况下诊断假体与患者不匹配：我们的研究是否错误？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37468193/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):e27.doi: 10.1016/j.jacc.2023.05.027。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468193/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37468193</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.027>10.1016/j.jacc.2023.05.027</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468193</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>博杨</dc:creator><dc:creator>-爱德华·P·陈</dc:creator><dc:creator>戈拉夫·艾拉瓦迪</dc:creator><dc:creator>——迈克尔·J·里尔登</dc:creator><dc:creator>G-迈克尔·迪布</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>在没有真正的超声心动图评估的情况下诊断假体与患者不匹配：我们的研究是否错误？</dc:title><dc:identifier>下午：37468193</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.027</dc:identifier></item><item><title>左心耳封堵术与直接口服抗凝剂治疗心房颤动的秋季结局</title><link/>https://pubmed.ncbi.nlm.nih.gov/37468192/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):379-381.doi:10.1016/j.jacc.2023.05.032。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468192/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37468192</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.032>10.1016/j.jacc.2023.05.032</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468192</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>邓文俊</dc:creator><dc:creator>穆萨·曼苏尔</dc:creator><dc:creator>宋波</dc:creator><dc:creator>侯海曼</dc:creator><dc:creator>刘凯</dc:creator><dc:creator>徐玉明</dc:creator><dc:creator>大卫·麦克穆林</dc:creator><dc:creator>费迪南多·S·博南诺</dc:creator><dc:creator>罗英华</dc:creator><dc:creator>明明宁</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>左心耳封堵术与直接口服抗凝剂治疗心房颤动的秋季结局</dc:title><dc:identifier>下午：37468192</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.032</dc:identifier></item><item><title>植入式心脏复律除颤器的开发：JACC 的历史性突破</title><link/>https://pubmed.ncbi.nlm.nih.gov/37468191/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description>植入式心律转复除颤器 (ICD) 代表了变革性技术，可以说是 50 年来心血管医学领域最重大的进步。先驱者 Mirowski 和 Mower 的远见和决心是这一巨大成就的基础，他们在资源有限的情况下开展工作，并面临来自医疗机构的怀疑/批评。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):353-373.doi:10.1016/j.jacc.2023.04.056。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">植入式心律转复除颤器 (ICD) 代表了变革性技术，可以说是 50 年来心血管医学领域最重大的进步。先驱者 Mirowski 和 Mower 的远见和决心是这一巨大成就的基础，他们在资源有限的情况下，面对来自医疗机构的怀疑/批评。室颤 (1980) 获得了美国食品和药物管理局的批准。经静脉导线系统将 ICD 从基于开胸术的二级预防转变为一级预防全世界无数患者都使用了猝死装置。前瞻性随机对照试验显示，ICD 的接受度优于抗心律失常药物。前瞻性随机对照试验显示，死亡率优于抗心律失常药物。只要有无畏的想象力，追求与公认智慧相冲突的新想法，医学领域就可以克服一切困难取得进展。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468191/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37468191</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.04.056>10.1016/j.jacc.2023.04.056</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468191</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>巴里·J·马龙</dc:creator><dc:creator>马克·埃斯蒂斯</dc:creator><dc:creator>伊森·J·罗文</dc:creator><dc:creator>马丁·S·马龙</dc:creator><dc:creator>——马修·R·雷诺兹</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>植入式心脏复律除颤器的开发：JACC 的历史性突破</dc:title><dc:identifier>下午：37468191</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.04.056</dc:identifier></item><item><title> Omega-3 脂肪酸与心房颤动的风险：大鱼还是小鱼？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37468190/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):350-352.doi:10.1016/j.jacc.2023.05.026。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468190/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37468190</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.026>10.1016/j.jacc.2023.05.026</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468190</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>克里斯蒂·M·巴兰坦</dc:creator><dc:creator>贾晓明</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>Omega-3 脂肪酸与心房颤动的风险：大鱼还是小鱼？</dc:title><dc:identifier>下午：37468190</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.026</dc:identifier></item><item><title> Omega-3 脂肪酸生物标志物和心房颤动事件</title><link/>https://pubmed.ncbi.nlm.nih.gov/37468189/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description>结论：体内 omega-3 脂肪酸（包括 EPA、DPA、DHA 和 EPA+DHA）水平与 AF 风险增加无关。我们的数据表明，习惯性饮食摄入 omega-3 脂肪酸对于 AF 风险是安全的。再加上这些脂肪酸在预防不良冠状动脉事件方面的已知益处，我们的研究表明，当前建议食用鱼/omega-3 脂肪酸的饮食指南可以维持下去。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):336-349.doi:10.1016/j.jacc.2023.05.024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：omega-3 脂肪酸与心房颤动 (AF) 之间的关系仍存在争议。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究旨在确定血液或脂肪组织中二十碳五烯酸 (EPA)、二十二碳五烯酸 (DPA) 和二十二碳六烯酸 (DHA) 水平与 AF 发生的前瞻性关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们使用了来自 17 项前瞻性队列研究的全球联盟的参与者级别数据，每项研究都有血液或脂肪组织 omega-3 脂肪酸水平和 AF 结果的基线数据。每项参与研究均使用预先指定的分析计划进行从头分析，该计划具有暴露、结果、协变量和亚组的统一定义。使用逆方差加权荟萃分析汇总关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在来自 17 个队列的 54,799 名参与者中，经过中位 13.3 年的随访，确定了 7,720 例 AF 事件。在多变量分析中，EPA 水平与 AF 事件无关，每五分位数范围的 HR（即第 90 个百分位数和第 10 个百分位数之间的差异）为 1.00（95% CI：0.95-1.05）。 DPA、DHA 和 EPA+DHA 的较高水平分别为 0.89 (95% CI: 0.83-0.95)、0.90 (95% CI: 0.85-0.96) 和 0.93 (95% CI: 0.87-0.99)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：体内 omega-3 脂肪酸（包括 EPA、DPA、DHA 和 EPA+DHA）水平与 AF 风险增加无关。我们的数据表明，习惯性饮食摄入 omega-3 脂肪酸对于 AF 风险是安全的。再加上这些脂肪酸在预防不良冠状动脉事件方面的已知益处，我们的研究表明，当前建议食用鱼/omega-3 脂肪酸的饮食指南可以维持下去。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468189/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37468189</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.024>10.1016/j.jacc.2023.05.024</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468189</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>钱方舟</dc:creator><dc:creator>——内森·廷特尔</dc:creator><dc:creator>保罗·詹森</dc:creator><dc:creator>罗森·N·勒梅特</dc:creator><dc:creator>今村文明</dc:creator><dc:creator>托比亚斯·鲁德霍尔姆·费尔德赖希</dc:creator><dc:creator>莎拉·奥普纳·野村</dc:creator><dc:creator>关伟华</dc:creator><dc:creator>费代丽卡·拉古兹</dc:creator><dc:creator>金恩静</dc:creator><dc:creator>于尔基·维尔塔宁</dc:creator><dc:creator>玛琳卡·斯图尔</dc:creator><dc:creator>克里斯蒂安·博克</dc:creator><dc:creator>平川阳一郎</dc:creator><dc:creator>米歇尔·L·奥多诺霍</dc:creator><dc:creator>阿莱克斯·萨拉·维拉</dc:creator><dc:creator>安德烈斯·阿迪森·科拉特</dc:creator><dc:creator>孙琪</dc:creator><dc:creator>埃里克·B·里姆</dc:creator><dc:creator>Bruce M Psaty更多</dc:creator><dc:creator>苏珊·R·赫克伯特</dc:creator><dc:creator>尼塔·G·福鲁希</dc:creator><dc:creator>尼古拉斯·J·韦勒姆</dc:creator><dc:creator>马蒂·马克伦德</dc:creator><dc:creator>乌尔夫·里瑟鲁斯</dc:creator><dc:creator>拉斯·林德</dc:creator><dc:creator>约翰·阿恩勒夫</dc:creator><dc:creator>帕文·加尔格</dc:creator><dc:creator>Michael Y Tsai更多</dc:creator><dc:creator>詹姆斯·潘科</dc:creator><dc:creator>杰弗里·R·米西亚莱克</dc:creator><dc:creator>布鲁纳·吉甘特</dc:creator><dc:creator>卡琳·利安德</dc:creator><dc:creator>朱莉·佩斯特</dc:creator><dc:creator>克里斯汀·M·阿尔伯特</dc:creator><dc:creator>玛丽亚姆·卡沃西</dc:creator><dc:creator>Arfan Ikram更多</dc:creator><dc:creator>特鲁迪·沃特曼</dc:creator><dc:creator>——埃里克·B·施密特</dc:creator><dc:creator>二宫敏晴</dc:creator><dc:creator>大卫·A·莫罗</dc:creator><dc:creator>安东尼·巴耶斯-热尼斯</dc:creator><dc:creator>詹姆斯·H·奥基夫</dc:creator><dc:creator>王国良</dc:creator><dc:creator>——吴杰森</dc:creator><dc:creator>达里乌什·莫扎法里安</dc:creator><dc:creator>威廉·S·哈里斯</dc:creator><dc:creator>大卫·S·西斯科维克</dc:creator><dc:creator>脂肪酸和结果研究联盟 (FORCE)</dc:creator><dc:date> 2023-07-19</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>Omega-3 脂肪酸生物标志物和心房颤动事件</dc:title><dc:identifier>下午：37468189</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.024</dc:identifier></item><item><title>心外膜脂肪来源的 miR92a-3p：减压疗法？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37468188/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):333-335.doi:10.1016/j.jacc.2023.05.030。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468188/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37468188</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.030>10.1016/j.jacc.2023.05.030</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468188</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>蒂莫西·菲茨吉本斯</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>心外膜脂肪来源的 miR92a-3p：减压疗法？</dc:title><dc:identifier>下午：37468188</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.030</dc:identifier></item><item><title>人心外膜脂肪组织来源的 miR-92a-3p 在心肌氧化还原状态中的作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37468187/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description>结论：EAT 来源的 miRNA 对人类心脏发挥旁分泌作用。事实上，miR-92a-3p 抑制无翅型 MMTV 整合位点家族、5a/Rac1/NADPH 氧化酶轴成员，并改善心肌氧化还原状态。EAT 来源的 miR-92a-3p 与改善临床结果相关，是预防和治疗肥胖相关心脏病的合理治疗靶点。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):317-332.doi:10.1016/j.jacc.2023.05.031。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：内脏肥胖与心血管风险增加直接相关，包括心力衰竭。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究探讨了人心外膜脂肪组织 (EAT) 衍生的 microRNA (miRNA) 调节心肌氧化还原状态和临床结果的能力。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：本研究筛选了人类 EAT 表达和释放的 miRNA，并在心脏手术患者的配对 EAT/心房活检标本中测试了与相邻心肌氧化还原状态的相关性。然后在体外心肌细胞模型中测试了三种 miRNA 的因果关系。在临床水平上，使用全基因组关联筛选来测试因果关系/方向性，并使用人类活检标本以及候选 miRNA 的过度表达来探索其潜在机制。使用转基因小鼠模型在体外和体内研究它们及其靶标。所发现靶标的最终预后价值在接受心脏手术的患者中进行了测试，并进行了中位随访 8 年。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：EAT miR-92a-3p 与人<sub>心肌</sub>中较低的氧化应激有关，这一发现通过使用人心脏中 miR-92a-3p 的遗传调节因子和<sup>EAT</sup>的 NADPH 氧化酶激活得到证实。最后，EAT 中的高 miR-92a-3p 水平与较低的不良心血管事件风险独立相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：EAT 来源的 miRNA 对人类心脏发挥旁分泌作用。事实上，miR-92a-3p 抑制无翅型 MMTV 整合位点家族、5a/Rac1/NADPH 氧化酶轴成员，并改善心肌氧化还原状态。EAT 来源的 miR-92a-3p 与改善临床结果相关，是预防和治疗肥胖相关心脏病的合理治疗靶点。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468187/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37468187</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.031>10.1016/j.jacc.2023.05.031</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468187</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>玛丽亚·克里斯蒂娜·卡雷纳</dc:creator><dc:creator>伊利亚娜·巴迪</dc:creator><dc:creator>默里·波尔金霍恩</dc:creator><dc:creator>扬尼斯·阿库米亚纳基斯</dc:creator><dc:creator>科斯塔斯·普萨罗斯</dc:creator><dc:creator>伊丽莎白·沃霍姆</dc:creator><dc:creator>克里斯托·P·科塔尼迪斯</dc:creator><dc:creator>纳迪亚·阿卡维</dc:creator><dc:creator>阿莱克修斯·安东诺普洛斯</dc:creator><dc:creator>贾加特·乔汉</dc:creator><dc:creator>拉纳·萨伊德</dc:creator><dc:creator>乔治·克拉索普洛斯</dc:creator><dc:creator>维韦克·斯里瓦斯塔瓦</dc:creator><dc:creator>沙基尔·法里德</dc:creator><dc:creator>——尼古拉斯·沃尔科特</dc:creator><dc:creator>阿娇道格拉斯</dc:creator><dc:creator>——基思·M·钱农</dc:creator><dc:creator>芭芭拉·卡萨迪</dc:creator><dc:creator>查拉兰博斯·安东尼亚德斯</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>人心外膜脂肪组织来源的 miR-92a-3p 在心肌氧化还原状态中的作用</dc:title><dc:identifier>下午：37468187</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.031</dc:identifier></item><item><title>完全血运重建与心绞痛的相互作用：越多越好？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37468186/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):314-316.doi:10.1016/j.jacc.2023.06.002。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468186/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37468186</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.002>10.1016/j.jacc.2023.06.002</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468186</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>优素福艾哈迈德</dc:creator><dc:creator>埃里克·委拉斯开兹</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>完全血运重建与心绞痛的相互作用：越多越好？</dc:title><dc:identifier>下午：37468186</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.002</dc:identifier></item><item><title>缺血试验中的完全血运重建和心绞痛相关健康状况</title><link/>https://pubmed.ncbi.nlm.nih.gov/37468185/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description>结论：在患有 ISCHEMIA 的 CCD 患者中，与 ICR 或 CON 相比，CR 的健康状况改善更多，尤其是那些经常发生心绞痛的患者。解剖学和功能性 CR 在生活质量方面提供了相当的改善。（内科和侵入性方法的健康有效性比较国际研究 [ISCHEMIA]；NCT01471522）。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):295-313.doi:10.1016/j.jacc.2023.05.025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：完全血运重建（CR）对慢性冠心病（CCD）心绞痛相关健康状况（症状、功能、生活质量）的影响尚未得到充分研究。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：在 ISCHEMIA 中随机接受侵入性 (INV) 与保守性 (CON) 治疗（内科和侵入性方法比较健康效果的国际研究）的 CCD 患者中，我们比较了以下内容：1) 与不完全血运重建 (ICR) 相比，解剖学和功能性 CR 对健康状况的影响；2) 与 CON 相比，所有 INV 患者实现 CR 的预测影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：采用针对患者特征进行多变量回归调整，比较接受血运重建的 INV 患者在独立核心实验室定义的 CR 与 ICR 后 12 个月的健康状况，然后进行倾向加权模型，以与 CON 相比，评估所有 INV 患者实现 CR 或 ICR 时的治疗效果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：1,641 名 INV 患者中分别有 43.3% 和 57.8% 获得了解剖学和功能性 CR。在进行血运重建的患者中，调整基线差异后，与 ICR 相比，CR 与西雅图心绞痛问卷心绞痛频率改善相关。在所有 INV 患者中建立 CR 和 ICR 模型后，CR 和 ICR 患者的健康状况均比 CON 患者有更大的改善，其中 CR 的健康状况比 ICR 更好。基线每日/每周心绞痛在那些没有心绞痛的人。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在患有 ISCHEMIA 的 CCD 患者中，与 ICR 或 CON 相比，CR 的健康状况改善更多，尤其是那些经常发生心绞痛的患者。解剖学和功能性 CR 在生活质量方面提供了相当的改善。（内科和侵入性方法的健康有效性比较国际研究 [ISCHEMIA]；NCT01471522）。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468185/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37468185</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.025>10.1016/j.jacc.2023.05.025</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468185</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>克雷顿·马夫罗马蒂斯</dc:creator><dc:creator>菲利普·G·琼斯</dc:creator><dc:creator>齐亚德·阿​​里</dc:creator><dc:creator>格雷格·W·斯通</dc:creator><dc:creator>——格蕾丝·M·罗兹</dc:creator><dc:creator>斯里帕尔·班加罗尔</dc:creator><dc:creator>肖恩·奥布莱恩</dc:creator><dc:creator>菲利普·杰内勒</dc:creator><dc:creator>詹妮弗·霍斯特</dc:creator><dc:creator>奥维迪乌·德雷斯勒</dc:creator><dc:creator>——肖恩·古德曼</dc:creator><dc:creator>凯伦·亚历山大</dc:creator><dc:creator>阿努普·马修</dc:creator><dc:creator>陈吉彦</dc:creator><dc:creator>巴尔拉姆·巴尔加瓦</dc:creator><dc:creator>Amar Uxa更多</dc:creator><dc:creator>威廉·博登</dc:creator><dc:creator>丹尼尔·B·马克</dc:creator><dc:creator>哈莫尼·R·雷诺兹</dc:creator><dc:creator>——大卫·J·马龙</dc:creator><dc:creator>——朱迪思·S·霍克曼</dc:creator><dc:creator>约翰·斯珀图斯</dc:creator><dc:creator>缺血研究组</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>缺血试验中的完全血运重建和心绞痛相关健康状况</dc:title><dc:identifier>下午：37468185</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.025</dc:identifier></item><item><title>三尖瓣经导管修复术：即将迎来黄金时代？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37468184/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):292-294.doi:10.1016/j.jacc.2023.05.028。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468184/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37468184</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.028>10.1016/j.jacc.2023.05.028</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468184</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>何塞普·罗德斯·卡包</dc:creator><dc:creator>詹姆斯·贾努齐</dc:creator><dc:creator>——迈克尔·J·麦克</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>三尖瓣经导管修复术：即将迎来黄金时代？</dc:title><dc:identifier>下午：37468184</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.028</dc:identifier></item><item><title>利用天然 T1 作图追踪心脏轻链淀粉样变性的治疗反应</title><link/>https://pubmed.ncbi.nlm.nih.gov/37466990/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description>结论和相关性：治疗反应中天然 T1 的变化反映了 T2 和 ECV 变化的综合结果，与传统心脏反应标志物的变化以及死亡率相关。然而，作为一项单中心研究，这些结果需要在更大的队列中进行外部验证。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 7 月 19 日。doi：10.1001/jamacardio.2023.2010。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：心脏磁共振 (CMR) 成像衍生的细胞外体积 (ECV) 测绘由造影前和造影后 T1 生成，可准确确定心脏轻链淀粉样变性的治疗反应。无需造影即可导出的原生 T1 测绘已证明诊断和预测的准确性，但尚不清楚连续原生 T1 测量是否也可以跟踪心脏治疗反应。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估原生 T1 映射是否可以测量心脏治疗反应以及原生 T1 变化与预后之间的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、背景和参与者：这项单中心队列研究评估了诊断为心脏轻链淀粉样变性的患者（2016 年 1 月至 2020 年 12 月），这些患者在诊断时接受了 CMR 扫描，并在化疗后接受了重复扫描。分析于 2016 年 1 月至 2022 年 10 月之间进行。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和措施：比较自然 T1 降低、稳定或增加的患者之间的生物标志物和心脏成像参数，以及自然 T1 变化与死亡率之间的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：该研究包括 221 名患者（平均 [SD] 年龄，64.7 [10.6] 岁；130 名男性 [59%]）。6 个月时，183 名患者（平均 [SD] 年龄，64.8 [10.5] 岁；110 名男性 [60%]）接受了重复 CMR 成像。8 名患者 (4%) 发生了 50 毫秒或更长的自然 T1 减少，所有患者均患有良好的血液学反应；相比之下，42 名患者 (23%) 出现自然 T1 增加 50 毫秒或更长，其中大多数血液学反应较差 (27 [68%])。12 个月时，160 名患者（平均 [SD] 年龄，63.8 [11.1] 岁；94 名男性 [59%]）进行了重复 CMR 扫描。%），所有患者都有良好的血液学反应，并且与N 端脑钠肽前体减少（中位数 [IQR]，2638 [913-5767] vs 423 [128-1777] ng/L；P &lt; .001），最大壁厚度（平均值 [SD]，14.8 [3.6] vs 13.6 [3.9] mm；P = .009）和 E/e&#39;（平均值 [SD]，14）减少.9 [6.8] 对比 12.0 [4.0]；P = .007），纵向应变改善（平均值 [SD]，-14.8% [4.0%] 对比 -16.7% [4.0%]；P = .004），心肌 T2（平均值 [SD]，52.3 [2.9] 对比 P &lt; .001）和 ECV（平均值 [SD]，0.47 [0.07]）降低] vs 0.42 [0.08]；P &lt; .001)。12 个月时，24 名患者 (15%) 出现天然 T1 增加，其中大多数患者血液学反应较差 (17 [71%])，并且与 N 端脑前钠利尿肽增加相关（中位数 [IQR]，1622 [554-5487] vs 3150 [1161-874] 5] ng/L；P = .007），左心室射血分数降低（平均 [SD]，65.8% [11.4%] vs 61.5% [12.4%]；P = .009），心肌 T2（平均 [SD]，52.5 [2.7] vs 55.3 [4.2] 毫秒；P &lt; .001）和 ECV（平均 [SD]）增加，0.48 [0.09] vs 0.56 [0.09]；P &lt; .001）。6 个月时心肌天然 T1 的变化与死亡率独立相关（风险比，2.41 [95% CI，1.36-4. 27]；P = .003）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：治疗反应中天然 T1 的变化反映了 T2 和 ECV 变化的综合结果，与传统心脏反应标志物的变化以及死亡率相关。然而，作为一项单中心研究，这些结果需要在更大的队列中进行外部验证。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37466990/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37466990</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2010>10.1001/jamacardio.2023.2010</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37466990</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>亚当·约安努</dc:creator><dc:creator>里希·K·帕特尔</dc:creator><dc:creator>安娜·马丁内斯-纳哈罗</dc:creator><dc:creator>优素福·拉兹维</dc:creator><dc:creator>阿尔多斯特法诺·波卡里</dc:creator><dc:creator>穆罕默德·U·拉乌夫 (Muhammad U Rauf)</dc:creator><dc:creator>鲁斯·博尔休斯</dc:creator><dc:creator>雅各布·费尔南多-塞耶斯</dc:creator><dc:creator>鲁塔·维辛斯凯特</dc:creator><dc:creator>弗朗西斯科·班德拉</dc:creator><dc:creator>图沙尔·科特查</dc:creator><dc:creator>露西娅·文内里</dc:creator><dc:creator>丹尼尔·奈特</dc:creator><dc:creator>夏洛特·马尼斯蒂</dc:creator><dc:creator>詹姆斯·穆恩</dc:creator><dc:creator>海伦·拉赫曼</dc:creator><dc:creator>卡罗尔·惠兰</dc:creator><dc:creator>彼得·凯尔曼</dc:creator><dc:creator>菲利普·N·霍金斯</dc:creator><dc:creator>朱利安·D·吉尔莫尔</dc:creator><dc:creator>阿舒托什·韦查莱卡</dc:creator><dc:creator>玛丽安娜丰塔纳</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>利用天然 T1 作图追踪心脏轻链淀粉样变性的治疗反应</dc:title><dc:identifier>下午：37466990</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2010</dc:identifier></item><item><title>轻链心脏淀粉样变性治疗中的成像生物标志物</title><link/>https://pubmed.ncbi.nlm.nih.gov/37466953/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 7 月 19 日。doi：10.1001/jamacardio.2023.2030。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37466953/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37466953</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2030>10.1001/jamacardio.2023.2030</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37466953</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>萨拉·AM·卡迪</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>轻链心脏淀粉样变性治疗中的成像生物标志物</dc:title><dc:identifier>下午：37466953</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2030</dc:identifier></item><item><title>与脑死亡相关的左心室功能障碍：供体心脏研究的结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/37465972/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230720142913&amp;v=2.17.9.post6+86293ac<description>结论：与脑死亡相关的左心室功能障碍发生在许多潜在的心脏捐赠者身上，有时是可逆的。这些发现可以为捐赠者评估期间做出的决策提供信息，并有助于指导捐赠者心脏接受移植。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 7 月 19 日。doi：10.1161/CIRCULATIONAHA.122.063400。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Left ventricular dysfunction in potential donors meeting brain death criteria often results in nonuse of donor hearts for transplantation, yet little is known about its incidence or pathophysiology. Resolving these unknowns was a primary aim of the DHS (Donor Heart Study), a multisite prospective cohort study. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: The DHS enrolled potential donors by neurologic determination of death (n=4333) at 8 organ procurement organizations across the United States between February 2015 and May 2020. Data included medications administered, serial diagnostic tests, and transthoracic echocardiograms (TTEs) performed: (1) within 48 hours after brain death was formally diagnosed; and (2) 24±6 hours later if left ventricular (LV) dysfunction was initially present. LV dysfunction was defined as an LV ejection fraction &lt;50% and was considered reversible if LV ejection fraction was >;50% on the second TTE. TTEs were also examined for presence of LV regional wall motion abnormalities and their reversibility. We assessed associations between LV dysfunction, donor heart acceptance for transplantation, and recipient 1-year survival. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: An initial TTE was interpreted for 3794 of the 4333 potential donors by neurologic determination of death. A total of 493 (13%) of these TTEs showed LV dysfunction. Among those donors with an initial TTE, LV dysfunction was associated with younger age, underweight, and higher NT-proBNP (N-terminal pro-B-type natriuretic peptide) and troponin levels. A second TTE was performed within 24±6 hours for a subset of donors (n=224) with initial LV dysfunction; within this subset, 130 (58%) demonstrated reversibility. Sixty percent of donor hearts with normal LV function were accepted for transplant compared with 56% of hearts with reversible LV dysfunction and 24% of hearts with nonreversible LV dysfunction. Donor LV dysfunction, whether reversible or not, was not associated with recipient 1-year survival. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: LV dysfunction associated with brain death occurs in many potential heart donors and is sometimes reversible. These findings can inform decisions made during donor evaluation and help guide donor heart acceptance for transplantation.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37465972/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37465972</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063400>10.1161/CIRCULATIONAHA.122.063400</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37465972</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Kiran K Khush</dc:creator><dc:creator> Darren Malinoski</dc:creator><dc:creator> Helen Luikart</dc:creator><dc:creator> Brian Wayda</dc:creator><dc:creator> Tahnee Groat</dc:creator><dc:creator> John Nguyen</dc:creator><dc:creator> John Belcher</dc:creator><dc:creator> Javier Nieto</dc:creator><dc:creator> Nikole Neidlinger</dc:creator><dc:creator> Ahmad Salehi</dc:creator><dc:creator> PJ Geraghty</dc:creator><dc:creator> Bruce Nicely</dc:creator><dc:creator> Martin Jendrisak</dc:creator><dc:creator> Thomas Pearson</dc:creator><dc:creator> R Patrick Wood</dc:creator><dc:creator> Shiqi Zhang</dc:creator><dc:creator> Yingjie Weng</dc:creator><dc:creator> Jonathan Zaroff</dc:creator><dc:date> 2023-07-19</dc:date><dc:source> Circulation</dc:source><dc:title> Left Ventricular Dysfunction Associated With Brain Death: Results From the Donor Heart Study</dc:title><dc:identifier> pmid:37465972</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.122.063400</dc:identifier></item><item><title> Intravascular imaging during percutaneous coronary intervention: temporal trends and clinical outcomes in the USA</title><link/> https://pubmed.ncbi.nlm.nih.gov/37464975/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720142913&amp;v=2.17.9.post6+86293ac<description> CONCLUSION: Among Medicare beneficiaries undergoing PCI, use of IVI has increased over the previous decade but remains relatively infrequent. IVI-guided PCI was associated with lower risk-adjusted mortality, acute MI, repeat PCI, and MACE. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 19:ehad430. doi: 10.1093/eurheartj/ehad430. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> AIMS: Prior trials have demonstrated that intravascular imaging (IVI)-guided percutaneous coronary intervention (PCI) results in less frequent target lesion revascularization and major adverse cardiovascular events (MACEs) compared with standard angiographic guidance. The uptake and associated outcomes of IVI-guided PCI in contemporary clinical practice in the USA remain unclear. Accordingly, temporal trends and comparative outcomes of IVI-guided PCI relative to PCI with angiographic guidance alone were examined in a broad, unselected population of Medicare beneficiaries. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS AND RESULTS: Retrospective cohort study of Medicare beneficiary data from 1 January 2013, through 31 December 2019 to evaluate temporal trends and comparative outcomes of IVI-guided PCI as compared with PCI with angiography guidance alone in both the inpatient and outpatient settings. The primary outcomes were 1 year mortality and MACE, defined as the composite of death, myocardial infarction (MI), repeat PCI, or coronary artery bypass graft surgery. Secondary outcomes were MI or repeat PCI at 1 year. Multivariable Cox regression was used to estimate the adjusted association between IVI guidance and outcomes. Falsification endpoints (hospitalized pneumonia and hip fracture) were used to assess for potential unmeasured confounding. The study population included 1 189 470 patients undergoing PCI (38.0% female, 89.8% White, 65.1% with MI). Overall, IVI was used in 10.5% of the PCIs, increasing from 9.5% in 2013% to 15.4% in 2019. Operator IVI use was variable, with the median operator use of IVI 3.92% (interquartile range 0.36%-12.82%). IVI use during PCI was associated with lower adjusted rates of 1 year mortality [adjusted hazard ratio (aHR) 0.96, 95% confidence interval (CI) 0.94-0.98], MI (aHR 0.97, 95% CI 0.95-0.99), repeat PCI (aHR 0.74, 95% CI 0.73-0.75), and MACE (aHR 0.85, 95% CI 0.84-0.86). There was no association with the falsification endpoint of hospitalized pneumonia (aHR 1.02, 95% CI 0.99-1.04) or hip fracture (aHR 1.02, 95% CI 0.94-1.10). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: Among Medicare beneficiaries undergoing PCI, use of IVI has increased over the previous decade but remains relatively infrequent. IVI-guided PCI was associated with lower risk-adjusted mortality, acute MI, repeat PCI, and MACE.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37464975/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37464975</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad430>10.1093/eurheartj/ehad430</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37464975</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Reza Fazel</dc:creator><dc:creator> Robert W Yeh</dc:creator><dc:creator> David J Cohen</dc:creator><dc:creator> Sunil V Rao</dc:creator><dc:creator> Siling Li</dc:creator><dc:creator> Yang Song</dc:creator><dc:creator> Eric A Secemsky</dc:creator><dc:date> 2023-07-19</dc:date><dc:source> European heart journal</dc:source><dc:title> Intravascular imaging during percutaneous coronary intervention: temporal trends and clinical outcomes in the USA</dc:title><dc:identifier> pmid:37464975</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad430</dc:identifier></item><item><title> Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries</title><link/> https://pubmed.ncbi.nlm.nih.gov/37464183/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720142913&amp;v=2.17.9.post6+86293ac<description> Artificial intelligence (AI) is likely to revolutionize the way medical images are analysed and has the potential to improve the identification and analysis of vulnerable or high-risk atherosclerotic plaques in coronary arteries, leading to advances in the treatment of coronary artery disease. However, coronary plaque analysis is challenging owing to cardiac and respiratory motion, as well as the small size of cardiovascular structures. Moreover, the analysis of coronary imaging data is... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol. 2023 Jul 18. doi: 10.1038/s41569-023-00900-3. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Artificial intelligence (AI) is likely to revolutionize the way medical images are analysed and has the potential to improve the identification and analysis of vulnerable or high-risk atherosclerotic plaques in coronary arteries, leading to advances in the treatment of coronary artery disease. However, coronary plaque analysis is challenging owing to cardiac and respiratory motion, as well as the small size of cardiovascular structures. Moreover, the analysis of coronary imaging data is time-consuming, can be performed only by clinicians with dedicated cardiovascular imaging training, and is subject to considerable interreader and intrareader variability. AI has the potential to improve the assessment of images of vulnerable plaque in coronary arteries, but requires robust development, testing and validation. Combining human expertise with AI might facilitate the reliable and valid interpretation of images obtained using CT, MRI, PET, intravascular ultrasonography and optical coherence tomography. In this Roadmap, we review existing evidence on the application of AI to the imaging of vulnerable plaque in coronary arteries and provide consensus recommendations developed by an interdisciplinary group of experts on AI and non-invasive and invasive coronary imaging. We also outline future requirements of AI technology to address bias, uncertainty, explainability and generalizability, which are all essential for the acceptance of AI and its clinical utility in handling the anticipated growing volume of coronary imaging procedures.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37464183/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37464183</a> | DOI: <a href=https://doi.org/10.1038/s41569-023-00900-3>10.1038/s41569-023-00900-3</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37464183</guid><pubDate> Tue, 18 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Bernhard Föllmer</dc:creator><dc:creator> Michelle C Williams</dc:creator><dc:creator> Damini Dey</dc:creator><dc:creator> Armin Arbab-Zadeh</dc:creator><dc:creator> Pál Maurovich-Horvat</dc:creator><dc:creator> Rick HJA Volleberg</dc:creator><dc:creator> Daniel Rueckert</dc:creator><dc:creator> Julia A Schnabel</dc:creator><dc:creator> David E Newby</dc:creator><dc:creator> Marc R Dweck</dc:creator><dc:creator> Giulio Guagliumi</dc:creator><dc:creator> Volkmar Falk</dc:creator><dc:creator> Aldo J Vázquez Mézquita</dc:creator><dc:creator> Federico Biavati</dc:creator><dc:creator> Ivana Išgum</dc:creator><dc:creator> Marc Dewey</dc:creator><dc:date> 2023-07-18</dc:date><dc:source> Nature reviews. Cardiology</dc:source><dc:title> Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries</dc:title><dc:identifier> pmid:37464183</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00900-3</dc:identifier></item><item><title> Microstructural and Microvascular Phenotype of Sarcomere Mutation Carriers and Overt Hypertrophic Cardiomyopathy</title><link/> https://pubmed.ncbi.nlm.nih.gov/37463608/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720142913&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Microstructural alteration and MVD occur in overt HCM and are different in G+ and G- patients. Both also occur in the absence of hypertrophy in sarcomeric mutation carriers, in whom changes are associated with electrocardiographic abnormalities. Measurable changes in myocardial microstructure and microvascular function are early-phenotype biomarkers in the emerging era of disease-modifying therapy. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Jul 18. doi: 10.1161/CIRCULATIONAHA.123.063835. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: In hypertrophic cardiomyopathy (HCM), myocyte disarray and microvascular disease (MVD) have been implicated in adverse events, and recent evidence suggests that these may occur early. As novel therapy provides promise for disease modification, detection of phenotype development is an emerging priority. To evaluate their utility as early and disease-specific biomarkers, we measured myocardial microstructure and MVD in 3 HCM groups-overt, either genotype-positive (G+LVH+) or genotype-negative (G-LVH+), and subclinical (G+LVH-) HCM-exploring relationships with electrical changes and genetic substrate. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: This was a multicenter collaboration to study 206 subjects: 101 patients with overt HCM (51 G+LVH+ and 50 G-LVH+), 77 patients with G+LVH-, and 28 matched healthy volunteers. All underwent 12-lead ECG, quantitative perfusion cardiac magnetic resonance imaging (measuring myocardial blood flow, myocardial perfusion reserve, and perfusion defects), and cardiac diffusion tensor imaging measuring fractional anisotropy (lower values expected with more disarray), mean diffusivity (reflecting myocyte packing/interstitial expansion), and second eigenvector angle (measuring sheetlet orientation). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Compared with healthy volunteers, patients with overt HCM had evidence of altered microstructure (lower fractional anisotropy, higher mean diffusivity, and higher second eigenvector angle; all <i>P</i> &lt;0.001) and MVD (lower stress myocardial blood flow and myocardial perfusion reserve; both <i>P</i> &lt;0.001). Patients with G-LVH+ were similar to those with G+LVH+ but had elevated second eigenvector angle ( <i>P</i> &lt;0.001 after adjustment for left ventricular hypertrophy and fibrosis). In overt disease, perfusion defects were found in all G+ but not all G- patients (100% [51/51] versus 82% [41/50]; <i>P</i> =0.001). Patients with G+LVH- compared with healthy volunteers similarly had altered microstructure, although to a lesser extent (all diffusion tensor imaging parameters; <i>P</i> &lt;0.001), and MVD (reduced stress myocardial blood flow [ <i>P</i> =0.015] with perfusion defects in 28% versus 0 healthy volunteers [ <i>P</i> =0.002]). Disarray and MVD were independently associated with pathological electrocardiographic abnormalities in both overt and subclinical disease after adjustment for fibrosis and left ventricular hypertrophy (overt: fractional anisotropy: odds ratio for an abnormal ECG, 3.3, <i>P</i> =0.01; stress myocardial blood flow: odds ratio, 2.8, <i>P</i> =0.015; subclinical: fractional anisotropy odds ratio, 4.0, <i>P</i> =0.001; myocardial perfusion reserve odds ratio, 2.2, <i>P</i> =0.049). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Microstructural alteration and MVD occur in overt HCM and are different in G+ and G- patients. Both also occur in the absence of hypertrophy in sarcomeric mutation carriers, in whom changes are associated with electrocardiographic abnormalities. Measurable changes in myocardial microstructure and microvascular function are early-phenotype biomarkers in the emerging era of disease-modifying therapy.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37463608/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37463608</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063835>10.1161/CIRCULATIONAHA.123.063835</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37463608</guid><pubDate> Tue, 18 Jul 2023 06:00:00 -0400</pubDate><dc:creator> George Joy</dc:creator><dc:creator> Christopher I Kelly</dc:creator><dc:creator> Matthew Webber</dc:creator><dc:creator> Iain Pierce</dc:creator><dc:creator> Irvin Teh</dc:creator><dc:creator> Louise McGrath</dc:creator><dc:creator> Paula Velazquez</dc:creator><dc:creator> Rebecca K Hughes</dc:creator><dc:creator> Huafrin Kotwal</dc:creator><dc:creator> Arka Das</dc:creator><dc:creator> Fiona Chan</dc:creator><dc:creator> Athanasios Bakalakos</dc:creator><dc:creator> Massimiliano Lorenzini</dc:creator><dc:creator> Konstantinos Savvatis</dc:creator><dc:creator> Sam A Mohiddin</dc:creator><dc:creator> Peter W Macfarlane</dc:creator><dc:creator> Michele Orini</dc:creator><dc:creator> Charlotte Manisty</dc:creator><dc:creator> Peter Kellman</dc:creator><dc:creator> Rhodri H Davies</dc:creator><dc:creator> Pier D Lambiase</dc:creator><dc:creator> Christopher Nguyen</dc:creator><dc:creator> Jurgen E Schneider</dc:creator><dc:creator> Maite Tomé</dc:creator><dc:creator> Gabriella Captur</dc:creator><dc:creator> Erica Dall&#39;Armellina</dc:creator><dc:creator> James C Moon</dc:creator><dc:creator> Luis R Lopes</dc:creator><dc:date> 2023-07-18</dc:date><dc:source> Circulation</dc:source><dc:title> Microstructural and Microvascular Phenotype of Sarcomere Mutation Carriers and Overt Hypertrophic Cardiomyopathy</dc:title><dc:identifier> pmid:37463608</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.063835</dc:identifier></item><item><title> Impact of Complete Revascularization in the ISCHEMIA Trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37462593/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720142913&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: The outcomes of an INV strategy may be improved if CR (especially ACR) is achieved. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches [ISCHEMIA]; NCT01471522). </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Jul 11:S0735-1097(23)06031-X. doi: 10.1016/j.jacc.2023.06.015. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Anatomic complete revascularization (ACR) and functional complete revascularization (FCR) have been associated with reduced death and myocardial infarction (MI) in some prior studies. The impact of complete revascularization (CR) in patients undergoing an invasive (INV) compared with a conservative (CON) management strategy has not been reported. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: Among patients with chronic coronary disease without prior coronary artery bypass grafting randomized to INV vs CON management in the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial, we examined the following: 1) the outcomes of ACR and FCR compared with incomplete revascularization; and 2) the potential impact of achieving CR in all INV patients compared with CON management. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: ACR and FCR in the INV group were assessed at an independent core laboratory. Multivariable-adjusted outcomes of CR were examined in INV patients. Inverse probability weighted modeling was then performed to estimate the treatment effect had CR been achieved in all INV patients compared with CON management. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: ACR and FCR were achieved in 43.4% and 58.4% of 1,824 INV patients. ACR was associated with reduced 4-year rates of cardiovascular death or MI compared with incomplete revascularization. By inverse probability weighted modeling, ACR in all 2,296 INV patients compared with 2,498 CON patients was associated with a lower 4-year rate of cardiovascular death or MI (difference -3.5; 95% CI: -7.2% to 0.0%). In comparison, the event rate difference of cardiovascular death or MI for INV minus CON in the overall ISCHEMIA trial was -2.4%. Results were similar but less pronounced with FCR. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: The outcomes of an INV strategy may be improved if CR (especially ACR) is achieved. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches [ISCHEMIA]; NCT01471522).</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37462593/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720142913&v=2.17.9.post6+86293ac">37462593</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.06.015>10.1016/j.jacc.2023.06.015</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37462593</guid><pubDate> Tue, 18 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Gregg W Stone</dc:creator><dc:creator> Ziad A Ali</dc:creator><dc:creator> Sean M O&#39;Brien</dc:creator><dc:creator> Grace Rhodes</dc:creator><dc:creator> Philippe Genereux</dc:creator><dc:creator> Sripal Bangalore</dc:creator><dc:creator> Kreton Mavromatis</dc:creator><dc:creator> Jennifer Horst</dc:creator><dc:creator> Ovidiu Dressler</dc:creator><dc:creator> Kian Keong Poh</dc:creator><dc:creator> Ranjit K Nath</dc:creator><dc:creator> Nagaraja Moorthy</dc:creator><dc:creator> Adam Witkowski</dc:creator><dc:creator> Sudhanshu K Dwivedi</dc:creator><dc:creator> Olga Bockeria</dc:creator><dc:creator> Jiyan Chen</dc:creator><dc:creator> Paola EP Smanio</dc:creator><dc:creator> Michael H Picard</dc:creator><dc:creator> Bernard R Chaitman</dc:creator><dc:creator> Daniel S Berman</dc:creator><dc:creator> Leslee J Shaw</dc:creator><dc:creator> William E Boden</dc:creator><dc:creator> Harvey D White</dc:creator><dc:creator> Stephen E Fremes</dc:creator><dc:creator> Yves Rosenberg</dc:creator><dc:creator> Harmony R Reynolds</dc:creator><dc:creator> John A Spertus</dc:creator><dc:creator> Judith S Hochman</dc:creator><dc:creator> David J Maron</dc:creator><dc:creator> ISCHEMIA Research Group</dc:creator><dc:date> 2023-07-18</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Impact of Complete Revascularization in the ISCHEMIA Trial</dc:title><dc:identifier> pmid:37462593</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.015</dc:identifier></item></channel></rss>